TW202325728A - 治療阿茲海默症之方法 - Google Patents

治療阿茲海默症之方法 Download PDF

Info

Publication number
TW202325728A
TW202325728A TW111142020A TW111142020A TW202325728A TW 202325728 A TW202325728 A TW 202325728A TW 111142020 A TW111142020 A TW 111142020A TW 111142020 A TW111142020 A TW 111142020A TW 202325728 A TW202325728 A TW 202325728A
Authority
TW
Taiwan
Prior art keywords
tau
plasma
antibody
human subject
dose
Prior art date
Application number
TW111142020A
Other languages
English (en)
Chinese (zh)
Inventor
蘿拉 尼森鮑姆
陳天樂
拉傑 拉賈戈文丹
Original Assignee
美商渤健麻塞諸塞州股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商渤健麻塞諸塞州股份有限公司 filed Critical 美商渤健麻塞諸塞州股份有限公司
Publication of TW202325728A publication Critical patent/TW202325728A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
TW111142020A 2021-11-03 2022-11-03 治療阿茲海默症之方法 TW202325728A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163275442P 2021-11-03 2021-11-03
US63/275,442 2021-11-03
US202163277127P 2021-11-08 2021-11-08
US63/277,127 2021-11-08
US202263309796P 2022-02-14 2022-02-14
US63/309,796 2022-02-14
US202263343029P 2022-05-17 2022-05-17
US63/343,029 2022-05-17

Publications (1)

Publication Number Publication Date
TW202325728A true TW202325728A (zh) 2023-07-01

Family

ID=86241855

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111142020A TW202325728A (zh) 2021-11-03 2022-11-03 治療阿茲海默症之方法

Country Status (5)

Country Link
US (1) US20240425573A1 (https=)
EP (1) EP4426349A4 (https=)
JP (1) JP2024540294A (https=)
TW (1) TW202325728A (https=)
WO (1) WO2023081194A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240753A1 (en) * 2024-05-16 2025-11-20 Creative Bio-Peptides, Inc. Peptides and therapies for treating neurological disorders
CN118777453B (zh) * 2024-06-25 2025-04-08 上海交通大学医学院附属瑞金医院 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) * 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
EP2560681A4 (en) * 2010-04-22 2013-09-25 Janssen Alzheimer Immunotherap USE OF TAU FOR MONITORING IMMUNOTHERAPY
WO2014011972A1 (en) * 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Tau immunoassay
NZ630542A (en) * 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
WO2021016466A1 (en) * 2019-07-24 2021-01-28 Duke University Compositions and methods for the diagnosis and treatment of alzheimer's disease
KR20220084095A (ko) * 2019-10-22 2022-06-21 바이오젠 엠에이 인코포레이티드 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체

Also Published As

Publication number Publication date
EP4426349A2 (en) 2024-09-11
WO2023081194A3 (en) 2023-10-26
EP4426349A4 (en) 2025-10-29
JP2024540294A (ja) 2024-10-31
US20240425573A1 (en) 2024-12-26
WO2023081194A2 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
US20220372123A1 (en) Anti-beta-amyloid antibody for treating alzheimer's disease
US20220281963A1 (en) Methods for treating alzheimer's disease
JP2020055880A (ja) アルツハイマー病の治療法
TW202317192A (zh) 用於阿茲海默氏症治療的生物標記物
TW202325728A (zh) 治療阿茲海默症之方法
TW202334201A (zh) 抗Tau抗體之組成物、劑型及方法
KR20240142535A (ko) P-tau181 수준을 사용한 치료 방법
CN120583962A (zh) 抗N3pGluβ淀粉样蛋白抗体、其剂量及其用途
KR20250114372A (ko) 타우(tau) pet 수준을 이용하는 치료 방법
US20250051427A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
CN120826223A (zh) 鲨肌醇与免疫治疗剂组合用于治疗阿尔茨海默氏病
US20240270830A1 (en) Methods for treating alzheimer's disease
CN118829445A (zh) 用于治疗阿尔茨海默病的方法
Krick et al. A Change of Mind: Targeting Amyloid-β with Better Safety Profile
WO2025240435A1 (en) Methods of treating neurological disorders with anti-abeta antibodies
WO2026057816A1 (en) Treatment of tauopathies with tau-binding antibodies
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку
NZ788486A (en) Methods for treating Alzheimer's disease